PMN
ProMIS Neurosciences Delivers Encouraging Interim Results from PRECISE-AD Trial and Advances Pipeline
ProMIS Neurosciences has made significant strides in its clinical development pipeline, with encouraging interim results from the phase I-B PRECISE-AD trial of PMN310, a monoclonal antibody designed to treat Alzheimer's disease. The company also reported progress on its other product candidates, including PMN267 for ALS and PMN442 for